Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-31072026-275036
EXTRAORDINARY
PART II-Section 3-Sub-section (ii)
PUBLISHED BY AUTHORITY
No. 4088]
NEW DELHI, FRIDAY, JULY 31, 2026/SHRAVAN 9, 1948
5921 GI/2026
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 31st July, 2026
S.O. 4264(E).— In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)
Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 and
S.O. 3516(E) dated 30th June, 2026 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the
National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes, the price as specified in column
(6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation
specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer
& marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
TABLE
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| Sl. | Name of the | Strength | Unit | Manufacturer & Marketing | Retail |
| No. | Formulation / | | | Company | Price |
| | Brand Name | | | | (Rs.) |
+=====+==================================+=============================================================+============+==========================================+=============+
| (1) | (2) | (3) | (4) | (5) | (6) |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Atorvastatin, | Each Hard Gelatin Capsule Contains: | | (i) M/s Akums Drugs & | |
| | Clopidogrel and | Atorvastatin Calcium IP Eq. to Atorvastatin 10 mg (As Film | | Pharmaceuticals Ltd./ | |
| 1 | Aspirin Capsules | Coated Atorvastatin Tablets IP), Clopidogrel Bisulphate IP | 1 Capsule | M/s Sun Pharma Laboratories Ltd.; | 6.37 |
| | | Eq. to Clopidogrel 75 mg (As Film Coated Clopidogrel | | (ii) M/s Akums Drugs & | |
| | | Tablets IP), Aspirin IP 75 mg (As Aspirin Gastro-Resistant | | Pharmaceuticals Ltd./ | |
| | | Tablets IP) | | M/s Sun Pharmaceutical Industries Ltd. | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Atorvastatin, | Each Hard Gelatin Capsule Contains: | | (i) M/s Akums Drugs & | |
| | Clopidogrel and | Atorvastatin Calcium IP Eq. to Atorvastatin 20 mg (As Film | | Pharmaceuticals Ltd./ | |
| 2 | Aspirin Capsules | Coated Atorvastatin Tablets IP, Clopidogrel Bisulphate IP | 1 Capsule | M/s Sun Pharma Laboratories Ltd.; | 8.89 |
| | | Eq. to Clopidogrel 75 mg (As Film Coated Clopidogrel | | (ii) M/s Akums Drugs & | |
| | | Tablets IP), Aspirin IP 75 mg (As Aspirin Gastro-Resistant | | Pharmaceuticals Ltd./ | |
| | | Tablets IP) | | M/s Sun Pharmaceutical Industries Ltd. | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Clonazepam and | Each Film Coated Bilayered Tablet Contains: | | M/s Akums Drugs & | |
| 3 | Paroxetine Controlled Release | Clonazepam IP 0.5 mg, Paroxetine Hydrochloride Hemihydrate | 1 Tablet | Pharmaceuticals Ltd./ | 17.52 |
| | Tablets | IP eq. to Paroxetine 12.5 mg (As Controlled Release) | | M/s Mankind Pharma Ltd. | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Clonazepam and | Each Film Coated Bilayered Tablet Contains: | | M/s Akums Drugs & | |
| 4 | Paroxetine Controlled Release | Clonazepam IP 0.5 mg, Paroxetine Hydrochloride Hemihydrate | 1 Tablet | Pharmaceuticals Ltd./ | 20.06 |
| | Tablets | IP eq. to Paroxetine 25 mg (As Controlled Release) | | M/s Mankind Pharma Ltd. | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Desvenlafaxine Extended Release | Each Uncoated Bilayered Tablet Contains: | | M/s Pure and Cure Healthcare Pvt. Ltd./ | |
| 5 | and Clonazepam Tablets | Desvenlafaxine Succinate USP Eq. to Desvenlafaxine 50 mg | 1 Tablet | M/s Mankind Pharma Ltd | 17.47 |
| | | (In Extended Release Form), Clonazepam IP 0.5 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Desvenlafaxine Extended Release | Each Uncoated Bilayered Tablet Contains: | | M/s Pure and Cure Healthcare Pvt. Ltd./ | |
| 6 | and Clonazepam Tablets | Desvenlafaxine Succinate USP Eq. to Desvenlafaxine 100mg | 1 Tablet | M/s Mankind Pharma Ltd | 25.83 |
| | | (In Extended-Release Form), Clonazepam IP 0.5 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Escitalopram Oxalate and | Each film coated tablet contains: Escitalopram Oxalate IP | | M/s Windlas Biotech Ltd./ | |
| 7 | Clonazepam Tablets | eq. to Escitalopram 5 mg, Clonazepam IP 0.5 mg | 1 Tablet | M/s Ipca Laboratories Ltd. | 10.72 |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Etoricoxib and Paracetamol | Each Film Coated Tablet contains: Etoricoxib IP 60 mg, | | M/s JK Print Pack (Pharma Division)/ | |
| 8 | Tablets | Paracetamol IP 325 mg | 1 Tablet | M/s Torrent Pharmaceuticals Ltd | 10.90 |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Ferrous Ascorbate and Folic Acid | Each film coated tablet contains: Ferrous Ascorbate IP eq. | | M/s Crius Life sciences Pvt. Ltd./ | |
| 9 | Tablets | to Elemental Iron 100 mg, Folic Acid IP 1.5 mg | 1 Tablet | M/s Eris Lifesciences Ltd. | 16.92 |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Iron and Folic Acid Syrup | Each 15 ml contains: Iron (III) Hydroxide Polymaltose | | M/s Skymap Pharmaceuticals Pvt. Ltd./ | |
| 10 | | complex eq. to Elemental Iron 50 mg, Folic Acid IP 0.5 mg | 1 ML | M/s German Remedies Pharmaceuticals | 0.28 |
| | | | | Pvt. Ltd. | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Myo-Inositol, D-Chiro Inositol | Each 5g Sachet contains: Vitamin D3 (Stabilized form) 1000 | | M/s Safetab Life Science/ | |
| 11 | and Vitamin D3 Powder | IU, Myo-Inositol IP 2000 mg, D-Chiro Inositol 50 mg | 1 GM | M/s Anax Lifescience Pvt. Ltd | 9.29 |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Ofloxacin and Metronidazole | Each 5 ml contains: Ofloxacin IP 100 mg, Metronidazole | | M/s Hema Laboratories Pvt. Ltd./ | |
| 12 | Suspension | Benzoate IP eq. to Metronidazole 200 mg | 1 ML | M/s Aristo Pharmaceuticals Pvt. Ltd. | 1.09 |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Ofloxacin and Metronidazole | Each 5 ml contains: Ofloxacin IP 50 mg, Metronidazole | | M/s Hema Laboratories Pvt. Ltd./ | |
| 13 | Suspension | Benzoate IP eq. to Metronidazole 100 mg | 1 ML | M/s Aristo Pharmaceuticals Pvt. Ltd. | 0.86 |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Paracetamol Oral Suspension | Each 5 ml contains: Paracetamol IP 500 mg | 1 ML | M/s Naxpar Pharma Pvt. Ltd. / | 0.66 |
| 14 | | | | M/s Glaxosmithkline Pharmaceuticals Ltd. | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Telmisartan and Metoprolol | Each film coated bilayered Tablet contains: Telmisartan IP | | M/s Windlas Biotech Ltd/ | |
| 15 | Succinate (ER) Tablets | 40 mg, Metoprolol Succinate IP eq. to Metoprolol Tartrate | 1 Tablet | M/s FDC Ltd | 15.01 |
| | | 25mg (as Extended release) | | | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Telmisartan and Metoprolol | Each film coated bilayered Tablet contains: Telmisartan IP | | M/s Windlas Biotech Ltd/ | |
| 16 | Succinate (ER) Tablets | 40 mg, Metoprolol Succinate IP eq. to Metoprolol Tartrate | 1 Tablet | M/s FDC Ltd | 18.50 |
| | | 50 mg (as Extended release) | | | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Telmisartan, Chlorthalidone and | Each film coated bilayer tablet contains: Telmisartan IP 40 | | M/s Mascot Health Series Pvt. Ltd./ | |
| 17 | Metoprolol Succinate (ER)Tablets | mg, Chlorthalidone IP 6.25 mg, Metoprolol Succinate IP | 1 Tablet | M/s Mankind Pharma Ltd. | 11.77 |
| | | 47.50 mg eq. to Metoprolol Tartrate 50 mg (As | | | |
| | | extended-release form) | | | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Telmisartan, Chlorthalidone and | Each film coated bilayer tablet contains: Telmisartan IP | | M/s Mascot Health Series Pvt. Ltd./ | |
| 18 | Metoprolol | 40mg, Chlorthalidone IP 6.25 mg, Metoprolol Succinate IP | 1 Tablet | M/s Mankind Pharma Ltd. | 11.67 |
| | | 23.75 mg eq. to Metoprolol Tartrate 25 mg (As | | | |
| | | extended-release form) | | | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Nebivolol Hydrochloride and | Each uncoated bilayered tablet contains: Nebivolol | | M/s Windlas Biotech Ltd./ | |
| 19 | Telmisartan Tablets | Hydrochloride IP Eq. to Nebivolol 2.5 mg, Telmisartan IP 40 | 1 Tablet | M/s Torrent Pharmaceuticals Ltd. | 13.70 |
| | | mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Sitagliptin, Glimepiride and | Each film coated tablet contains: Sitagliptin Phosphate | | (i) M/s Exemed Pharmaceuticals/ | |
| | Metformin Hydrochloride | Monohydrate IP eq. to Sitagliptin 100 mg, Glimepiride IP | | M/s Alkem Laboratories Ltd.; | |
| 20 | Extended-Release Tablets | 2mg, Metformin Hydrochloride (As Extended Release) IP 1000 | 1 Tablet | (ii) M/s Exemed Pharmaceuticals/ | 19.46 |
| | | mg | | M/s Sun Pharma Laboratories Ltd.; | |
| | | | | (iii) M/s Exemed Pharmaceuticals/ | |
| | | | | M/s Torrent Pharmaceuticals Ltd. | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Sitagliptin, Glimepiride and | Each film coated tablet contains: Sitagliptin Phosphate | | (i) M/s Exemed Pharmaceuticals/ | |
| | Metformin Hydrochloride | Monohydrate IP eq. to Sitagliptin 100 mg, Glimepiride IP | | M/s Alkem Laboratories Ltd.; | |
| 21 | Extended-Release Tablets | 1 mg, Metformin Hydrochloride (As Extended Release) IP 1000 | 1 Tablet | (ii) M/s Exemed Pharmaceuticals/ | 17.73 |
| | | mg | | M/s Sun Pharma Laboratories Ltd.; | |
| | | | | (iii) M/s Exemed Pharmaceuticals/ | |
| | | | | M/s Torrent Pharmaceuticals Ltd. | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Combikit of Clarithromycin | Each Strip Contains: A. Clarithromycin Tablets IP | | M/s Malik Lifesciences Pvt. Ltd. / | |
| | Tablets IP, Pantoprazole | (2 Tablets) Each Film Coated Tablet Contains: | | M/s Aristo Pharmaceuticals Pvt. Ltd. | 122.56 |
| 22 | Tablets IP and Amoxicillin | Clarithromycin IP 500 mg, B. Pantoprazole Tablets IP | 1 Strip | | |
| | Tablets USP | (2 Tablets) Each Enteric Coated Tablet Contains: | | | |
| | | Pantoprazole Sodium IP eq. to Pantoprazole 40 mg, | | | |
| | | C. Amoxicillin Tablets USP (2 Tablets) Each Film Coated | | | |
| | | Tablet Contains: Amoxycillin Trihydrate IP eq. to | | | |
| | | Amoxycillin 1000 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
| | Dapagliflozin, Pioglitazone and | Each film coated bilayered tablet contains: Dapagliflozin | | M/s Eris Lifesciences Ltd. | |
| 23 | Metformin Hydrochloride SR | Propanediol USP Eq. to Dapagliflozin 10mg, Pioglitazone | 1 Tablet | | 18.77 |
| | Tablets | Hydrochloride IP eq. to Pioglitazone 15mg, Metformin | | | |
| | | Hydrochloride IP (as sustained release) 1000mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+------------+------------------------------------------+-------------+
Notes:
(a) The manufacturer, as mentioned in column (5) of the table above, of formulations i.e., "new drug" under
paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price not exceeding the price as specified in column
(6) of the table above.
(b) Any other existing manufacturer launching the same new drug as specified in column (2), (3) and (4) of table
above within twelve months of the date of publication of this notification in the Official Gazette is permitted
to do so at a retail price not exceeding the price as specified in column (6) of the table above subject to filing
of Form-IA on IPDMS 2.0 along with supporting documents within one month of launch.
(c) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (6) of the above said table.
(d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of notification
as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller
and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business
in a manner so as to be easily accessible to any person wishing to consult the same.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification
and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit
the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the
Essential Commodities Act, 1955.
[PN/281/149/2026/F/F. No. 8(149)/2026/D.P./NPPA-Div.-II]
BHIVA RAM YADAV, Assistant Director
Login to read full text